key: cord-0978046-fihwfrxx
authors: Li, Li-Hsin; Liesenborghs, Laurens; Wang, Lanjiao; Lox, Marleen; Yakass, Michael Bright; Jansen, Sander; Rosales Rosas, Ana Lucia; Zhang, Xin; Thibaut, Hendrik Jan; Teuwen, Dirk; Neyts, Johan; Delang, Leen; Dallmeier, Kai
title: Biodistribution and Environmental Safety of a Live-attenuated YF17D-vectored SARS-CoV-2 Vaccine Candidate
date: 2022-01-26
journal: bioRxiv
DOI: 10.1101/2022.01.24.477505
sha: f46df44688472c648deff63bd40c2e0665645a7c
doc_id: 978046
cord_uid: fihwfrxx

New platforms are urgently needed for the design of novel prophylactic vaccines and advanced immune therapies. Live-attenuated yellow fever vaccine YF17D serves as vector for several licensed vaccines and platform for novel vaccine candidates. Based on YF17D, we developed YF-S0 as exceptionally potent COVID-19 vaccine candidate. However, use of such live RNA virus vaccines raises safety concerns, i.e., adverse events linked to original YF17D (yellow fever vaccine-associated neurotropic; YEL-AND, and viscerotropic disease; YEL-AVD). In this study, we investigated the biodistribution and shedding of YF-S0 in hamsters. Likewise, we introduced hamsters deficient in STAT2 signaling as new preclinical model of YEL-AND/AVD. Compared to parental YF17D, YF-S0 showed an improved safety with limited dissemination to brain and visceral tissues, absent or low viremia, and no shedding of infectious virus. Considering yellow fever virus is transmitted by Aedes mosquitoes, any inadvertent exposure to the live recombinant vector via mosquito bites is to be excluded. The transmission risk of YF-S0 was hence evaluated in comparison to readily transmitting YFV-Asibi strain and non-transmitting YF17D vaccine, with no evidence for productive infection of vector mosquitoes. The overall favorable safety profile of YF-S0 is expected to translate to other novel vaccines that are based on the same YF17D platform.

Roughly two years after first emergence in 2019/2020, more than 5 million people have 47 succumbed to Coronavirus Disease 2019 caused by Severe Acute 48

Syndrome Coronavirus 2 (SARS-CoV-2) 49 (https://coronavirus.jhu.edu/map.html). Mass immunization is key to mitigating the 50 expanding pandemic [1] . A set of rapidly developed prophylactic vaccines plays a 51 crucial role in global immunization against SARS-CoV-2. Several of these vaccines are 52 first-in-class based on novel platforms, including game changer mRNA vaccines and 53 viral vector vaccines that are unprecedented in both, their high clinical efficacy as well 54 as the incremental advance in breakthrough innovation [2] [3] [4] . However, a global 55 vaccine supply shortage, the dependence on an ultra-cold chain system in case of 56 mRNA vaccines, and the continuous emergence of virus variants pose unmet 57 challenges [5, 6] . Unfortunately, long-term effectiveness of current SARS-CoV-2 58 vaccines is waning due to the combined effect of (i) a rapid decay of virus-neutralizing 59 antibodies (nAb) over time and (ii) emergence of new variants escaping vaccine-60 induced immunity [7] [8] [9] . Furthermore, several first-generation COVID-19 vaccines 61 have a rather high reactogenicity. With the growing number of vaccinated people, more 62 cases and a wider spectrum of adverse effects following immunization (AEFI), 63 including severe adverse effects (SAE) such a myocarditis or life-threatening deep-64 venous thrombosis are described [10] [11] [12] [13] [14] [15] . In summary, there is an urgent to develop 65 new and improved second-generation COVID-19 vaccines to quench the pandemic. 66

Recently, we used an alternative vaccine platform that uses the fully replication 67 competent live-attenuated yellow fever vaccine YF17D as vector [16] and developed 68 a virus-vectored SARS-CoV-2 vaccine candidate (YF-S0) that expresses a stabilized 69 prefusion form of SARS-CoV-2 spike protein (S0) [17] . YF-S0 was shown to induce 70 vigorous humoral and cellular immune responses in hamsters (Mesocricetus auratus), 71 mice (Mus musculus) and cynomolgus macaques (Macaca fascicularis) and was able 72 to prevent COVID19-like disease after single-dose vaccination in a stringent hamster 73 model. Due to its YF17D backbone, YF-S0 could serve as dual vaccine to also prevent 74 yellow fever virus (YFV) infections, which should provide an added benefit for 75 populations living in regions at risk of YFV outbreaks [18] . 76

For our assessment, we chose wild-type (WT) Syrian golden hamsters as preferred 113 small animal model of YFV infection [24] and injected them with a high dose (10 4 PFU) 114 of either YF17D (n=6) or YF-S0 (n=6) via intraperitoneal route to achieve maximal 115 exposure; with primary pharmacodynamics documented before [17] and confirmed 116 here by consistently high seroconversion rates (at least 80%) to YFV-specific nAb (Fig.  117   S1 ). As methods control, we inoculated STAT2-knockout (STAT2 -/-) hamsters with 10 4 118 PFU of YF17D (n=2). STAT2 -/hamsters are deficient in antiviral type I and type III 119 interferon responses [25] and therefore prone to uncontrolled flavivirus replication [26] . 120

Tissues sampled for analysis were chosen based on biodistribution data available from 121 non-human primates and humans. In macaques, detection of YF17D RNA has been 122 reported in lymph nodes, spleen and liver at 7 days post subcutaneous inoculation 123

[27]. Likewise, viral RNA is widespread and abundantly found in spleen, liver, brain, 124 kidney, and other organs in patients who developed YEL-AVD [20, 28] . Based on this 125 knowledge, we collected spleen, liver, brain, and kidney as most common target 126 organs to assess the risks for YEL-AVD and YEL-AND. Ileum and parotid gland were 127 collected as additional excretory tissues, and lung as main target of COVID19 (Fig.  128 1A). From our previous experience [17] , we observed that the replication of YF17D or 129 YF-S0 is transient and well tolerated in WT hamsters. Tissue analysis in hamsters was 130 thus performed 7 days post inoculation (dpi), i.e., few days after peak of viremia and 131 at a timepoint which STAT2 -/hamsters needed to be euthanized for humane reasons. 132 Viral RNA above detection limits in YF17D vaccinated WT hamsters was mostly limited 133 to spleen (4/6), with exception of a single hamster in which viral RNA was widespread 134 to brain, parotid gland, and lung ( Fig. 1B and Suppl Table 1 ). Detection of YF-S0 was 135 markedly less frequent and restricted to only kidney (2/6) and lung (1/6) ( Fig. 1B and  136 Fig . 1D ). Overall, in either group RNA level was low and barely detectable by sensitive 137 RT-qPCR, indicative for limited replication in WT hamsters. In contrast, unrestricted 138 replication of virus to high viral loads was observed in STAT2 −/− hamsters ( Fig. 1B and  139 Fig . 1C ). Importantly, no viral RNA nor infectious virus could be detected in brains of 140 YF-S0 vaccinated hamsters, suggesting a low associated YEL-AND risk ( Fig. 1D and 141 Viremia is considered a key indicator for the risk of developing YEL-AVD. Kinetics of 143 viral RNA in serum as proxy for viremia have been reported earlier for WT hamsters 144 vaccinated with YF17D or YF-S0 [17] and are discussed here in comparison to 145 respective data from STAT2 -/controls (Fig. 2B ). Viremia can be detected consistently 146 in all YF17D vaccinated WT hamsters (6/6) starting at 1 dpi and lasting for 2.5 (1-4) 147 days in median (95% confidence interval); by contrast, viral RNA was detected only 148 once at 3 dpi in a single YF-S0 vaccinated hamster (1/6) ( Fig. 2B and Suppl. Table 2) . 149

In STAT2 -/hamsters, YF17D grew unrestrictedly to markedly increased viral RNA 150 levels ( Fig. 2B) , readily detectable by virus isolation (Fig. S2 ). Integration of data over 151 and on day 14 dissemination in head, legs and wings (dissemination). 184

Experimental feeding was equally efficient for all three virus groups regarding both viral 185 RNA and infectious virus recovered (Fig. 3B&C ). However, 14 days after feeding, viral 186 RNA was detected exclusively in specimens from the YF17D group (8/15) and YF-187

Asibi group (8/23); yet none from the YF-S0 group. Importantly, infectious viral particles 188 were only detectable in the YF-Asibi group, with virus loads as high as about 10 6 189 TCID50/body on average (Fig. 3C ). For dissemination beyond the MEB, the remaining 190 head, legs and wings of each six virus-positive mosquitoes with highest body virus 191 loads from the YF17D and YF-Asibi groups, respectively, and six randomly chosen 192 specimens from the YF-S0 group were evaluated. All these specimens from the Asibi group (6/6) scored positive for dissemination, while none from the YF-S0 or 194 YF17D groups ( Fig. 3B -C). The results showing that YF-S0 is neither able to pass the 195 MIB for midgut infection, nor to escape from the midgut (MEB) for dissemination (Fig. 196 3D&E) . To temper the remaining safety concerns, the viscerotropism and neurovirulence of 226 YF-S0 was compared head-to-head with parental YF17D virus by investigating the 227 biodistribution and viremia following administration of either vaccine virus in hamsters. 228

We demonstrate that parental YF17D can spread systemically and viral RNA can be 229 detected in spleen, brain, parotid gland, and lung in YF17D vaccinated WT hamsters. 230

However, replication of YF17D remains restricted, resulting in infectious virus loads 231 below detection limits. Compared to YF17D, detection of YF-S0 was further limited, 232 with minute amounts of viral RNA in kidney and lung. Unrestricted virus replication to 233 high viral loads as cause of viscerotropic or neurotropic disease was observed only in 234 STAT2 −/− hamsters, in line with the essential role innate interferon signaling plays in 235 live vaccines [30, 43] and control of viral infections in general [44] . In addition, in YF-236 S0 vaccinated WT hamsters, detection of viremia was rare (Fig. 2B) and importantly, 237 less frequent (1/6) and markedly lower in magnitude (AUC) and duration (1 day) 238 compared to parental YF17D (6/6 for >2 days). Taken together, the overall limited 239 tissue distribution of YF-S0 as well as the low abundance of its RNA in blood, below Altogether, YF-S0 is considered a safe and efficacious vaccine candidate for the 265 prevention of COVID19. A similar improved safety as compared to parental YF17D can 266 be expected for other vaccines following the same design principle, i.e., using 267

transgenic, yet fully replication-competent YF17D as vector [16, 40] . 

We thank Thibault Francken, Dagmar Buyst, Niels Cremers, Birgit Voeten, and Jasper 299

Rymenants for their technical support on specimens' preparation and virus titration as 300 well as Jasmine Paulissen for her technical assistance on generating serology data. 301

All data supporting the findings in this study are available from the corresponding 303 author upon request. 304

The authors declare that there are no competing interests. This manuscript is 306 currently under peer review. Asibi from an infectious cDNA clone will be described elsewhere (Yakass, Jansen et 335 al.). The respective YFV cDNA sequence was adjusted to match previously described 336 molecular clone Ap7M [46] . All virus stocks were titrated by plaque assay on BHK21 337 cells [17] . 338 WT hamsters (6-8 weeks old, female) were inoculated intraperitoneally with 10 4 340 PFU/mL dose of YF17D (n = 6) or YF-S0 (n = 6). STAT2 −/− hamster (6-8 weeks old, 341 female) were inoculated intraperitoneally with 10 4 PFU/mL of YF17D (n = 2). At 7 dpi, 342 blood, spleen, liver, brain, kidney, ileum, parotid gland, and lung were collected. 343

WT hamsters (6-8 weeks old, female) were inoculated intraperitoneally with 10 4 345 PFU/mL of YF17D (n = 6) or YF-S0 (n = 6). STAT2 −/− hamsters (6-8 weeks old, male) 346

were inoculated intraperitoneally with 10 4 PFU/mL of YF17D (n = 3). Blood, urine, 347 faces, and buccal swab were collected daily for the first 5 dpi, then every other day 348 until 11 dpi and 15, 22 (except for the blood) and 29 dpi, and afterwards once a week 349 until 29 dpi. 350

Ae. aegypti Paea [47] were obtained via the Infravec2 consortium 353 (https://infravec2.eu/product/live-eggs-or-adult-females-of-aedes-aegypti-strain-paea-354 2/) from Institute Pasteur of Paris. Mosquitoes were maintained at the insectary of 355

Rega Institute, and the fourth generation was used for this study. In brief, larvae were 356 fed with yeast tablets (Gayelord Hauser, France) until the pupae stage prior to transfer 357 to cages for emergence. Adults were maintained with cotton soaked in 10% sucrose 358 solution under standard conditions (28˚C, 80% relative humidity, and 14h:10h 359 light/dark cycle). 360

7-day-old female mosquitoes were starved 24 h prior to infection. Infectious blood 362 meals contained rabbit erythrocytes plus 5 mM adenosine triphosphate as 363 phagostimulant, supplemented with virus stocks to final titers of 2x10 5 PFU/mL for both 364 YF17D and YF-S0, and 5x10 6 PFU/mL for YF-Asibi, respectively. After 45 minutes, 5 365 full engorged females from each group were frozen for viral input assessment 366 (ingestion check, Fig. 3A) , and the rest kept with 10% of sugar solution under both 367 controlled conditions (28 ± 1°C, relative humidity of 80%, light/dark cycle of 14h/10h, 368 supplied with 10% sucrose solution) and BSL-3 containment conditions. At 14 dpi, mosquitoes were dissected into two parts; main body (thorax and abdomen) and 370 remainder, collected individually in tubes containing PBS and 2.8 mm ceramic beads 371 (Precellys). The samples were homogenized and pass through 0.8µm column filters 372 (Sartorius, Germany). Thus, cleared supernatants were used for TCID50 assay or keep 373 at -80°C for RNA extraction and subsequent RT-qPCR analysis. 374

Solid tissues (organs), faeces and buccal swabs were homogenized in a bead mill 376 (Precellys) in lysis buffer (Macherey-Nagel; cat no. 740984.10). After homogenization, 377 samples were centrifuged at 10,000 rpm for 5 min to remove cell debris, and total RNA 378 was extracted by using NucleoSpin Plus RNA virus Kit (Macherey-Nagel, cat no. System (Applied Biosystems). Absolute quantification was based on standard curves 386 generated from 5-fold serial dilutions of YF17D cDNA with a known concentration. 387

For virus isolation and quantification BHK21 cells were infected with 10-fold serial 389 dilutions in 96-well plates, and incubated at 37˚C for 6 days using DMEM with 2% fetal 390 bovine serum (Hyclone), 2 mM L-glutamine (Gibco), 1% sodium bicarbonate (Gibco), 391 and 1% antibiotics (PenStrep) as assay medium. Solid tissues were homogenized in 392 a bead mill (Precellys) in assay medium, and centrifuged at 10,000 rpm for 5 min (4˚C) 393 to remove debris. Resulting viral titers were calculated by the Reed and Muench 394 method. 395

Titers of YFV-specific neutralizing antibodies were determined using BHK21 cells and 397 a mCherry-tagged variant of YF17D virus (YFV-mCherry) as described [17] . In brief, YFV-mCherry was mixed and incubated with serial diluted of sera for 1 h at 37°C, and 399 subsequently transferred to BHK21 cells grown in 96-well plates for infection. At 3 days 400 post infection, the relative infection rate was quantified by counting mCherry-401 expressing cells versus total cells on a high content screening platform (CX5, Thermo 402

Fischer Scientific), normalizing the infection rate of untreated virus controls as 100%. 403

Half-maximal serum neutralizing titers (SNT50) were determined by curve fitting in 404 Fig. 1A and Fig. 2A) . YFV-specific humoral immune responses in one-dose YF17D and YF-S0 vaccinated WT hamsters (primary pharmacodynamics). Serum samples for determination of YFV-specific neutralizing antibodies (nAb) collected at the respective endpoint of experiments assessing vaccine virus biodistribution (Fig.1A , 7 dpi) and shedding ( Fig. 2A, 29 dpi) . Sample number in biodistribution experiment: Sham n=4, YF17D n=6, and YF-S0 n=6, and in shedding experiment: Sham n=4, YF17D n=5, and YF-S0 n=5. 50% serum neutralizing titers (SNT 50 ) were presented as median ± IQR for each group at logarithmic scale. Mann-Whitney test was used for the statistical analysis, with p >0.05 marked as non-significant (ns). Fig. 2A) . Infectious virus loads in serum (viremia) in selected YF17D or YF-S0 vaccinated hamsters. Serum samples collected at 3 days after vaccination. Sample number for YF17D vaccinated WT hamster, n=2; for YF-S0 vaccinated WT hamster, n=1; and (3) YF17D vaccinated STAT2 -/hamster, n=2. Selected samples included specimen with respectively highest viral RNA copies numbers detected (YF17D in WT and STAT2 -/hamsters) or, in case of YF-S0, the only PCR positive specimen. Fig. 2A ). Cumulative detection rates of viral RNA by RT-qPCR in all specimens (serum, urine, faeces or buccal swab) collected from vaccinated WT or STAT2 -/hamster. Specimens were collected according to sampling scheme depicted in Fig. 2A . Heatmap showing ratios of the total number of all PCR-positive samples versus the total number of all samples tested per study group over the course of 29 days after vaccination.

COVID-19 and the intensive care unit: 413 vaccines to the rescue

Distinguishing features of current COVID-19 415 vaccines: knowns and unknowns of antigen presentation and modes of action. 416 npj Vaccines

The dawn of mRNA vaccines: The COVID-19 case

The potential of adenoviral vaccine vectors with altered 420 antigen presentation capabilities. Expert review of vaccines

Challenges in creating herd immunity to SARS-CoV-2 423 infection by mass vaccination. The Lancet

Neutralising antibody titres as predictors of protection against 428 SARS-CoV-2 variants and the impact of boosting: a meta-analysis. The Lancet 429 Microbe

The efficacy of COVID-19 vaccines against the B. 1.617. 2 (delta) 431 variant. Molecular Therapy

COVID-19 vaccines: concerns beyond protective efficacy and 433 safety

A comprehensive analysis of the efficacy and safety of COVID-435 19 vaccines

Use of COVID-19 vaccines after reports of adverse 437 events among adult recipients of Janssen (Johnson & Johnson) and mRNA 438 COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory 439 Committee on Immunization Practices-United States

COVID-19 vaccines and thrombosis with thrombocytopenia 442 syndrome. Expert Review of Vaccines

Thrombotic adverse events reported for Moderna, Pfizer and 444 Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and 445 clinical outcomes in the EudraVigilance database. Vaccines

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-448 19 vaccination

Myocarditis after Covid-19 vaccination in a large health care 450 organization

The yellow fever 17D virus as a 452 platform for new live attenuated vaccines. Human vaccines & 453 immunotherapeutics

A single-dose live-attenuated YF17D-vectored 455 SARS-CoV-2 vaccine candidate

The Present and Future of Yellow Fever 457 Vaccines

Live virus vaccines based on a yellow fever vaccine 459 backbone: standardized template with key considerations for a risk/benefit 460 assessment

Yellow fever vaccine-how does it work and 462 why do rare cases of serious adverse events take place? Current opinion in 463 immunology

Risk of yellow fever virus transmission in the Asia-465 Pacific region

Substitution of Wild-Type Yellow Fever Asibi Sequences 467 for 17D Vaccine Sequences in ChimeriVax-Dengue 4 Does Not Enhance 468 Infection of Aedes aegypti Mosquitoes. The Journal of infectious diseases

Midgut barriers prevent the replication and dissemination of the 471 yellow fever vaccine in Aedes aegypti. PLoS neglected tropical diseases

Animal models of yellow fever and their application in clinical 474 research. Current opinion in virology

STAT2 signaling restricts viral dissemination but drives 476 severe pneumonia in SARS-CoV-2 infected hamsters

Zika virus infection of adult and fetal STAT2 knock-out 479 hamsters

A live, attenuated recombinant West Nile virus vaccine

Immunity and immune response, pathology and 483 pathologic changes: progress and challenges in the immunopathology of yellow 484 fever. Reviews in medical virology

Detection of yellow fever 17D genome in urine

Inherited IFNAR1 deficiency in otherwise healthy patients 488 with adverse reaction to measles and yellow fever live vaccines. The Journal of 489 experimental medicine

Tissue barriers to arbovirus infection in mosquitoes. Viruses

Dissecting vectorial capacity for mosquito-borne 493 viruses. Current opinion in virology

Learning immunology from the yellow fever vaccine: innate 495 immunity to systems vaccinology

Clinical development of IMOJEV®-a 498 recombinant Japanese encephalitis chimeric vaccine (JE-CV)

Phase II, randomized, double-blind, placebo-controlled, 503 multicenter study to investigate the immunogenicity and safety of a West Nile 504 virus vaccine in healthy adults